- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07948200
Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer (EPIRE)
Urinary DNA Methylation Testing (Bladder EpiCheck®) and Its Peri-operative Kinetics for the Prediction of Residual Disease at Second Transurethral Resection in T1 Non-muscle-invasive Bladder Cancer The EPIRE Study
European Association of Urology (EAU) guidelines mandate a second transurethral resection of bladder tumour (re-TURBt) for patients with high-grade or pT1 non-muscle-invasive bladder cancer (NMIBC) to eradicate residual disease and avoid understaging. However, 30% to 50% or more of patients undergoing re-TURBt have no residual tumour found upon re-resection, incurring surgical and anaesthetic risks, potential morbidity, healthcare costs, and delays in adjuvant therapy without direct oncological benefit.
Current non-invasive triage tools, such as urine cytology and office cystoscopy, suffer from low sensitivity or diagnostic ambiguity due to ongoing post-operative inflammation and tissue healing in a recently resected bladder. While novel molecular biomarkers like Bladder EpiCheck® demonstrate high sensitivity and negative predictive value in the surveillance setting, single-timepoint measurements shortly after resection struggle to differentiate transient, healing-induced epigenetic changes from true persistent malignancy.
Evaluating the longitudinal trajectory of the EpiScore across two distinct post-operative timepoints (T1 and T2) provides a physiological basis for distinguishing decaying inflammatory/reparative signals from stable or rising signals indicative of residual disease. Demonstrating the diagnostic accuracy of Bladder EpiCheck® at T2, alongside the dynamic change in EpiScore (ΔEpiScore), will establish whether non-invasive urine biomarker testing can reliably select low-risk pT1 NMIBC patients in whom re-TURBt can be safely omitted.
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Gian Luca De Salvo, MD
- Telefonszám: 0498215704
- E-mail: clinical.trial@iov.veneto.it
Tanulmányozza a kapcsolattartók biztonsági mentését
- Név: Antonio Amodeo, MD
- Telefonszám: 0423421321
- E-mail: antonio.amodeo@iov.veneto.it
Tanulmányi helyek
-
-
Italy/Padova
-
Padova, Italy/Padova, Olaszország, 35128
- Istituto Oncologico Veneto
-
Kapcsolatba lépni:
- Antonio Amodeo, MD
- Telefonszám: 0423421321
- E-mail: antonio.amodeo@iov.veneto.it
-
Kapcsolatba lépni:
- Francesco Claps, MD
- Telefonszám: 0423421321
- E-mail: francesco.claps@iov.veneto.it
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- age ≥18 years;
- histologically confirmed pT1 urothelial carcinoma of the bladder (any grade, WHO 2022 and 1973 classifications) on the definitive histology of the initial TURBt;
- macroscopically complete initial resection as reported by the surgeon, with detrusor muscle present in the specimen, both formally documented in the operative and pathology records;
- indication for second TURBt according to EAU guidelines, with the procedure scheduled at the study centre and expected within ten weeks of the initial TURBt;
- clinically localised non-metastatic disease (cN0, cM0);
- patients able to provide written informed consent.
- Previous BCG treatment is allowed.
Exclusion Criteria:
- muscle-invasive disease (≥pT2) on the definitive histology of the initial TURBt;
- initial resection judged incomplete by the operating surgeon - whether because visible tumour was deliberately left behind or because the procedure had to be curtailed and a planned second look arranged - or absence of detrusor muscle in the specimen - these patients receive second TURBt per guidelines but are outside the study question, which concerns the completely resected patient;
- pure non-urothelial histology (primary adenocarcinoma, pure squamous cell carcinoma, small cell neuroendocrine carcinoma, sarcoma). Variant histologies of urothelial carcinoma are not an exclusion criterion but are recorded as a covariate;
- concomitant upper tract urothelial carcinoma, or a history of it within the preceding 24 months, given the documented positivity of Bladder EpiCheck® in that disease [19];
- A single early post-operative chemotherapy instillation, where given, is not an exclusion criterion but is recorded as a covariate;
- previous pelvic radiotherapy;
- indwelling urinary catheter or intermittent self-catheterisation; urinary diversion or neobladder;
- clinically non-localised disease (cN+, cM+);
- pregnancy or breastfeeding;
- TURBt performed in an emergency setting for uncontrolled bleeding or other life-threatening indication, in which resection quality cannot be assured;
- second TURBt not performed at the study centre, with consequent unavailability of the reference standard;
- patients unable to provide written informed consent, or any condition that in the investigator's judgement compromises the ability to comply with study procedures.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Diagnosztikai
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: EPIRE
|
The investigational IVD medical device evaluated as the index test is the Bladder EpiCheck® system (manufactured by Nucleix Ltd.; exclusive Italian distributor: A. Menarini Diagnostics s.r.l.). The assay is CE-IVD marked under Directive 98/79/EC (Annex III, General IVD category) and cleared by the US FDA via the 510(k) pathway. The manufacturer operates under a certified UNI CEI EN ISO 13485:2016 quality management system. Bladder EpiCheck® profiles the DNA methylation patterns of 15 proprietary DNA biomarkers on genomic DNA isolated from the cellular pellet of a voided urine sample. The assay protocol involves DNA extraction, digestion with a methylation-sensitive restriction enzyme, and subsequent multiplex real-time polymerase chain reaction (multiplex real-time PCR). Dedicated analysis software generates a quantitative integrative score termed the EpiScore, on a continuous scale from 0 to 100. In accordance with the manufacturer's Instructions for Use (IFU), the qualitative diagno |
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T2 for residual disease at second TURBt in T1 NMIBC patients.
Időkeret: Through study completion, an average of 2 years
|
Diagnostic accuracy of EpiScore at T2 (categorized as > 60 positive vs ≤ 60 negative) evaluated against central histopathology review of the second TURBt, measured as Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value (NPV), Accuracy, and Likelihood Ratios. |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of change EpiScore between the two subsequent timepoints T1 and T2.
Időkeret: Through study completion, an average of 2 years
|
Average daily rate of change in EpiScore, calculated as ∆EpiScore=(T2-T1)/(Days between T1 and T2) evaluated against second TURBt residual disease status using a univariate logistic regression model and Area Under the ROC Curve (AUC) with 95% CI. |
Through study completion, an average of 2 years
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Diagnostic accuracy of Bladder EpiCheck® test at timepoint T1
Időkeret: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of EpiScore at T1 (> 60 vs ≤ 60) for residual disease at second TURBt |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of urinary cytology at timepoints T1 and T2
Időkeret: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, Accuracy, and Likelihood Ratios (95% CI) of urinary cytology (Paris System classification) at T1 and T2 against second TURBt histopathology |
Through study completion, an average of 2 years
|
|
Agreement at T1 and T2 between Bladder EpiCheck® and urinary cytology
Időkeret: Through study completion, an average of 2 years
|
Concordance between Bladder EpiCheck® and urinary cytology at T1 and T2, quantified by Cohen's kappa (κ) coefficient. |
Through study completion, an average of 2 years
|
|
Agreement between T1 and T2 of Bladder EpiCheck®;
Időkeret: Through study completion, an average of 2 years
|
Agreement on paired aliquots of Bladder EpiCheck® between timepoints T1 and T2 with McNemar's test for paired data |
Through study completion, an average of 2 years
|
|
Agreement between T1 and T2 of urinary cytology
Időkeret: Through study completion, an average of 2 years
|
Agreement on paired aliquots of urinary cytology between timepoints T1 and T2 with McNemar's test for paired data |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy at T1 and T2 of the combination of Bladder EpiCheck® and urinary cytology, defined in two versions: (1) as negative when both are negative, (2) as negative when at least one is negative
Időkeret: Through study completion, an average of 2 years
|
Sensitivity, Specificity, PPV, NPV, and Accuracy at T1 and T2 evaluated under two combination definitions: (1) negative when both tests are negative; (2) negative when at least one test is negative |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy in the previous settings for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt;
Időkeret: Through study completion, an average of 2 years
|
Diagnostic accuracy measures (Sensitivity, Specificity, PPV, NPV) of tests and combinations specifically for predicting high-grade disease, ≥ pT1, and/or concomitant Carcinoma in Situ (CIS) at second TURBt |
Through study completion, an average of 2 years
|
|
Diagnostic accuracy of alternative definitions of change in EpiScore
Időkeret: Through study completion, an average of 2 years
|
Diagnostic accuracy and AUC for alternative definitions of Episcore change between T1 and T2: absolute difference (T2-T1) and relative percentage change (T2-T1)/T1; |
Through study completion, an average of 2 years
|
|
Change in positivity rate of Bladder EpiCheck® and urinary cytology between T1 and T2 among patients whose second TURBt is negative.
Időkeret: Through study completion, an average of 2 years
|
9) Proportion of test positivity change between T1 and T2 in patients without residual disease (measuring the clearance rate of post-operative false positives). |
Through study completion, an average of 2 years
|
Együttműködők és nyomozók
Szponzor
Együttműködők
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Urogenitális betegségek
- Urogenitális neoplazmák
- Neoplazmák webhelyenként
- Neoplazmák
- Férfi urogenitális betegségek
- Urológiai betegségek
- Női urogenitális betegségek
- Női urogenitális betegségek és terhességi szövődmények
- Neoplazmák szövettani típus szerint
- Neoplazmák, mirigyes és epiteliális
- Urológiai neoplazmák
- Karcinóma
- Húgyhólyag-betegségek
- A húgyhólyag-daganatok
- Nem izominvazív hólyag-daganatok
Egyéb vizsgálati azonosító számok
- IOV-NMIBC-02-2026-EPIRE
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .